Compare BridgeBio Pharma Inc (BBIO) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs D R Horton Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while D R Horton Inc trades at $150.79 (market cap $41.02B). The key difference: D R Horton Inc is far larger — about 2.5× BridgeBio Pharma Inc's market cap, and D R Horton Inc pays a 1.23% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DHI | |
|---|---|---|
Market Cap | $16.61B | $41.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $184.04 |
52-Week Low | $47.29 | $132.53 |
Enterprise Value | $18.16B | $46.13B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
D.R. Horton (DHI) trades at $151.08, up 3.47% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance amid persistent affordability pressures. Valuation metrics appear reasonable with a P/E of 14.4 and P/S of 1.32, while profitability remains solid with a net income margin of 9.15%.
The outlook is mixed: strong execution and cash returns provide support, but weaker demand and margin pressure pose headwinds. Investment opportunity lies in disciplined inventory management and shareholder returns, while risks include elevated mortgage rates and competitive threats from disruptors like Boxabl. Analyst sentiment is balanced with 45% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
